BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1429 related articles for article (PubMed ID: 20616679)

  • 1. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
    Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
    Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
    Russo V; Barone A; Conte E; Prascina F; Stella A; Noci ND
    Retina; 2009 Apr; 29(4):511-5. PubMed ID: 19174717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
    Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
    Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
    Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
    Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of bevacizumab as the primary treatment for retinal vein occlusions.
    Figueroa MS; Contreras I; Noval S; Arruabarrena C
    Br J Ophthalmol; 2010 Aug; 94(8):1052-6. PubMed ID: 20679089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.